Literature DB >> 24609803

Diagnostic accuracy of MOC-31 for malignant effusions: a meta-analysis.

Diandian Li1, Bo Wang, Qianjing Hu, Yongchun Shen, Dan Xu, Tao Wang, Fuqiang Wen.   

Abstract

Numerous studies have investigated the utility of MOC-31 in the diagnosis of malignant effusions. However, the results remain controversial. The aim of this study is to determine the overall accuracy of MOC-31 for malignant effusions through a meta-analysis of published studies. Publications addressing the accuracy of MOC-31 in the diagnosis of malignant effusions were selected from the PubMed, Embase, and Cochrane Library. Data from selected studies were pooled to yield summary sensitivity, specificity, positive and negative likelihood ratios (LRs), diagnostic odds ratio (DOR), and receiver operating characteristic (SROC) curve. Statistical analysis was performed by Meta-Disc 1.4 and STATA 12.0 software. Eighteen studies, based on 1,748 patients, met the inclusion criteria for the meta-analysis, and the summary estimating for MOC-31 in the diagnosis of malignant effusions were sensitivity 0.85 (95%CI 0.83-0.87), specificity 0.97 (95%CI 0.96-0.99), positive likelihood ratio (PLR) 23.81 (95%CI 15.59-36.37), negative likelihood ratio (NLR) 0.12 (95%CI 0.07-0.20), and diagnostic odds ratio 214.18 (95%CI 99.96-458.93). The SROC curve indicated that the maximum joint sensitivity and specificity (Q value) was 0.95; the area under the curve was 0.98. Our findings suggest that MOC-31 may be a useful diagnostic tool with high sensitivity and specificity for differentiating malignant effusions and benign effusions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24609803     DOI: 10.1007/s13277-014-1795-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  37 in total

1.  The diagnostic odds ratio: a single indicator of test performance.

Authors:  Afina S Glas; Jeroen G Lijmer; Martin H Prins; Gouke J Bonsel; Patrick M M Bossuyt
Journal:  J Clin Epidemiol       Date:  2003-11       Impact factor: 6.437

2.  Diagnostic utility of MOC-31, HBME-1 and MOC-31 mRNA in distinguishing between carcinoma cells and reactive mesothelial cells in pleural effusions.

Authors:  Ying Sun; Guang-Ping Wu; Chang-Qing Fang; Shu-Li Liu
Journal:  Acta Cytol       Date:  2009 Nov-Dec       Impact factor: 2.319

Review 3.  Understanding heterogeneity in meta-analysis: the role of meta-regression.

Authors:  W L Baker; C Michael White; J C Cappelleri; J Kluger; C I Coleman
Journal:  Int J Clin Pract       Date:  2009-10       Impact factor: 2.503

4.  Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells.

Authors:  T Ruitenbeek; A S Gouw; S Poppema
Journal:  Arch Pathol Lab Med       Date:  1994-03       Impact factor: 5.534

Review 5.  Diagnosis of pleural effusion: a systematic approach.

Authors:  Emmet E McGrath; Paul B Anderson
Journal:  Am J Crit Care       Date:  2011-03       Impact factor: 2.228

Review 6.  The diagnostic and molecular characteristics of malignant mesothelioma and ovarian/peritoneal serous carcinoma.

Authors:  B Davidson
Journal:  Cytopathology       Date:  2010-11-30       Impact factor: 2.073

7.  Comparison of three cytologic preparation methods and immunocytochemistries to distinguish adenocarcinoma cells from reactive mesothelial cells in serous effusion.

Authors:  Junko Ueda; Takako Iwata; Midori Ono; Mutsuo Takahashi
Journal:  Diagn Cytopathol       Date:  2006-01       Impact factor: 1.582

Review 8.  Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis.

Authors:  Q-L Liang; H-Z Shi; X-J Qin; X-D Liang; J Jiang; H-B Yang
Journal:  Thorax       Date:  2007-06-15       Impact factor: 9.139

Review 9.  Management of malignant pleural effusion.

Authors:  Jack A Kastelik
Journal:  Lung       Date:  2013-01-13       Impact factor: 2.584

10.  Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis.

Authors:  Huan-Zhong Shi; Qiu-Li Liang; Jing Jiang; Xue-Jun Qin; Hai-Bo Yang
Journal:  Respirology       Date:  2008-04-14       Impact factor: 6.424

View more
  5 in total

1.  Diagnostic value of IMP3 in pancreatic cancer: a meta-analysis.

Authors:  Qianqian Wang; Tao Wang; Zhu Wang; Hong Zheng
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  Anti-EpCAM antibodies for detection of metastatic carcinoma in effusions and peritoneal wash.

Authors:  Fabiana Pirani Carneiro; Maria Imaculada Muniz-Junqueira; Marcos De Vasconcelos Carneiro; Ísis De Araújo Oliveira; Aluízio Carlos Soares; Nathália De Vargas Haar; Gustavo Henrique Soares Takano; Leonora Maciel De Sousa Vianna; Guilherme De Carvalho Caldas; Danillo Leal Marinho Vieira; Lígia Lins Frutuoso; Larissa Matos Rodrigues Brito; Rafael Vieira Martins De Siqueira; Amanda Moreira Parente; Tercia Maria Mendes Lousa De Castro; Isabela Peres; Lianna Martha Soares Mendes; Tatiana Karla Dos Santos Borges; Vânia Moraes Ferreira; Andrea Barretto Motoyama
Journal:  Oncol Lett       Date:  2019-06-12       Impact factor: 2.967

3.  Diagnostic value of mesothelinin pancreatic cancer: a meta-analysis.

Authors:  Lin Zhu; Yiling Liu; Guangyuan Chen
Journal:  Int J Clin Exp Med       Date:  2014-11-15

4.  Homocysteine: new tumor marker in pleural fluid.

Authors:  Jose D Santotoribio; Consuelo Cañavate-Solano; Angela Garcia-de la Torre; Luis Del Valle-Vazquez; Francisco Arce-Matute; Juan F Cuadros-Muñoz; Maria J Sanchez del Pino; Manuel J Bandez-Ruiz; Carmen Piñuela-Rojas; Santiago Perez-Ramos
Journal:  Tumour Biol       Date:  2015-05-09

5.  The diagnostic value of pleural fluid homocysteine in malignant pleural effusion.

Authors:  Jose D Santotoribio; Luis Del Valle-Vazquez; Angela García-de la Torre; Daniel Del Castillo-Otero; Juan-Bosco Lopez-Saez; Maria J Sanchez Del Pino
Journal:  PLoS One       Date:  2019-09-24       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.